VistaGen Therapeutics, Inc.
VTGN
$2.22
-$0.12-5.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -121.87% | -96.74% | -55.48% | 22.13% | 34.95% |
| Total Depreciation and Amortization | 12.59% | 12.95% | 8.63% | 6.24% | 8.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 92.90% | 66.44% | 100.53% | -87.30% | -38.45% |
| Change in Net Operating Assets | 180.17% | 391.08% | 15.80% | 262.40% | 184.49% |
| Cash from Operations | -116.56% | -75.86% | -37.74% | 3.70% | 52.21% |
| Capital Expenditure | 100.00% | -- | -- | -- | -156.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,218.75% | -- | -- | 94.56% | -156.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.32% | 100.32% |
| Issuance of Common Stock | -99.10% | -- | 2,100.00% | -- | 1,853,657.14% |
| Repurchase of Common Stock | -- | -- | -- | -33,660.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.75% | -100.00% | -89.94% | 57.78% | 30,922.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.71% | -166.72% | -131.58% | 11.97% | 967.83% |